HomeClene (CLNN) CEO On Biopharmaceutical Company & Earnings Beat
Clene (CLNN) CEO On Biopharmaceutical Company & Earnings Beat

Clene (CLNN) stock was up around 3% today. Recent earnings report indicated $0.42 in EPS and $110K in revenue, beating estimates. CEO, Rob Etherington, says that the biopharmaceutical company focuses on neurodegenerative diseases. What are the plans for the company's future growth, and how will the CLNN stock price continue to perform?

The Watch List

18 Nov 2021

ON AIR
education
5:30 am
Your First Trade
replay
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
3:30 am
Trading 360
REPLAY
4:30 am
Next Gen Investing
REPLAY
ON AIR
education
5:30 am
Your First Trade
REPLAY
6:00 am
Fast Market
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
education
3:30 pm
Your First Trade
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
education
7:00 pm
Your First Trade
REPLAY
7:30 pm
Trading 360
REPLAY
8:30 pm
Fast Market
REPLAY
9:30 pm
Next Gen Investing
REPLAY
education
10:30 pm
Your First Trade
REPLAY
11:00 pm
Trading 360
REPLAY

Get Market Minute

Daily insights for every investor

FOLLOW US